DrugPatentWatch Database Preview
Investigational Drug Information for LGX818
Email this page to a colleague
What is the development status for investigational drug LGX818?
LGX818 is an investigational drug.
There have been 28 clinical trials for LGX818.
The most recent clinical trial was a Phase 2 trial, which was initiated on December 13th 2013.
The most common disease conditions in clinical trials are Melanoma, Colorectal Neoplasms, and Neoplasms. The leading clinical trial sponsors are Array BioPharma, Pfizer, and National Cancer Institute (NCI).
There are two hundred and thirty US patents protecting this investigational drug and two international patents.
Summary for LGX818
| US Patents | 230 |
| International Patents | 2,044 |
| US Patent Applications | 764 |
| WIPO Patent Applications | 675 |
| Japanese Patent Applications | 202 |
| Clinical Trial Progress | Phase 2 (2013-12-13) |
| Vendors | 38 |
Recent Clinical Trials for LGX818
| Title | Sponsor | Phase |
|---|---|---|
| Phase 1 Safety Study of Encorafenib in Chinese Patients With Advanced Metastatic BRAF V600E Mutant Solid Tumors | Pierre Fabre Medicament | Phase 1 |
| A Study Evaluating the Combination of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or Infusional 5-fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab in Chinese Patients With BRAF V600E Mutant Metastatic Colorectal Cancer. | Merck KGaA, Darmstadt, Germany | Phase 2 |
| A Study Evaluating the Combination of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or Infusional 5-fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab in Chinese Patients With BRAF V600E Mutant Metastatic Colorectal Cancer. | Pierre Fabre Medicament | Phase 2 |
Clinical Trial Summary for LGX818
Top disease conditions for LGX818
Top clinical trial sponsors for LGX818
US Patents for LGX818
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| LGX818 | ⤷ Sign up for a Free Trial | Compounds and compositions as protein kinase inhibitors | Array BioPharma Inc. (Boulder, CO) | ⤷ Sign up for a Free Trial |
| LGX818 | ⤷ Sign up for a Free Trial | Small molecule HSP70 inhibitors | The Trustees of the University of Pennsylvania (Philadelphia, PA) The Wistar Institute of Anatomy and Biology (Philadelphia, PA) | ⤷ Sign up for a Free Trial |
| LGX818 | ⤷ Sign up for a Free Trial | Compounds and compositions as inhibitors of MEK | Novartis AG (Basel, CH) | ⤷ Sign up for a Free Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for LGX818
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| LGX818 | Argentina | AR077975 | 2029-08-28 | ⤷ Sign up for a Free Trial |
| LGX818 | Australia | AU2010286569 | 2029-08-28 | ⤷ Sign up for a Free Trial |
| LGX818 | Brazil | BR112012004453 | 2029-08-28 | ⤷ Sign up for a Free Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
